Study of Danicopan in Participants With Hepatic Impairment
Status:
Completed
Trial end date:
2018-09-21
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK)
of ACH-0144471 (danicopan) in participants with hepatic impairment (HI) as compared to
healthy matched participants.